"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia.

Epidiolex is the first FDA-approved treatment in the U.S. that contains a purified drug substance derived from marijuana -- CBD -- and the first treatment for Dravet syndrome. In September 2018 the FDA rescheduled cannabidiol from a C-I controlled substance to a C-V controlled substance, meaning it has a proven medical use but a low risk of abuse. This change allows Epidiolex to be marketed in the U.S.

CBD likewise communicates with a neurotransmitter called GABA (gamma-aminobutyric corrosive). GABA transfers messages from one brain cell, or neuron, to another; that message usually is “Back off” or “stop pushing.” GABA advises the body when it’s a great opportunity to shut down, and since a huge number of neurons in the cerebrum react to GABA, the impacts include lessening anxiety, quieting the sensory system, assisting with rest, unwinding the muscles.
A. When a product is in violation of the FD&C Act, FDA considers many factors in deciding whether or not to initiate an enforcement action. Those factors include, among other things, agency resources and the threat to the public health. FDA also may consult with its federal and state partners in making decisions about whether to initiate a federal enforcement action.

AC/DC: A Sativa-dominant phenotype of Cannatonic, this cultivar boasts one of the highest ratios of CBD to THC, clocking in at 20:1. AC/DC is claimed to help reduce pain, anxiety, depression and migraines while reducing symptoms in patients with epilepsy, some forms of cancer, and multiple sclerosis. This cultivar’s pinene-rich terpene profile offers potent clear-headed pain relief.

Colored impurities from the oil can be removed by adding activated charcoal to about one third to one half the weight or volume of the solvent containing the dissolved oil, mixing well, filtering, and evaporating the solvent.[2] When decolorizing fatty oils, oil retention can be up to 50 wt % on bleaching earths and nearly 100 wt % on activated charcoal.[20]
Marijuana can produce acute psychotic episodes at high doses, and several studies have linked marijuana use to increased risk for chronic psychosis in individuals with specific genetic risk factors. Research suggests that these effects are mediated by THC, and it has been suggested that CBD may mitigate these effects.xxxi There have been a few small-scale clinical trials in which patients with psychotic symptoms were treated with CBD, including case reports of patients with schizophrenia that reported conflicting results; a small case study in patients with Parkinson’s disease with psychosis, which reported positive results; and one small randomized clinical trial reporting clinical improvement in patients with schizophrenia treated with CBD.xxxii Large randomized clinical trials would be needed to fully evaluate the therapeutic potential of CBD for patients with schizophrenia and other forms of psychosis.